Valuation: Physiomics Plc

Market Cap 2.33M 3.18M 2.73M 2.56M 4.4M 303M 4.45M 30.14M 11.73M 153M 11.95M 11.69M 507M P/E 2026 *
-5.15x
P/E 2027 * -
Enterprise Value 2.07M 2.82M 2.42M 2.26M 3.9M 269M 3.94M 26.71M 10.4M 136M 10.59M 10.36M 449M EV / Sales 2026 *
2.07x
EV / Sales 2027 * -
Free-Float
73.34%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Physiomics Plc

Manager TitleAgeSince
Director of Finance/CFO 52 -
Chief Operating Officer - 30/06/2026
Corporate Officer/Principal - 30/08/2021
Director TitleAgeSince
Director/Board Member - 28/04/2026
Chairman 53 28/04/2026
Director/Board Member - 28/04/2026
Change 5-day change 1-year change 3-year change Capi.($)
+0.39%+1.86%-21.32%+11.31% 128B
+0.57%+0.25%-41.02%-17.06% 45.15B
-0.21%-0.33%-1.41%+5.87% 41B
-0.88%-0.51%-22.81%-4.38% 22.54B
-1.24%-2.80%-38.25%-37.91% 18.08B
-0.83%+1.27%-5.01%+6.17% 16.29B
-0.43%-1.36%+2.86%+58.24% 16.28B
-1.54%-1.93%-23.07%-31.86% 10.53B
+0.07%-16.39%+11.95%+39.25% 3.42B
Average -0.50%+2.14%-15.34%+3.29% 33.44B
Weighted average by Cap. -0.07%+3.80%-20.18%+3.25%

Financials

2026 *2027 *
Net sales 1M 1.36M 1.17M 1.09M 1.89M 130M 1.91M 12.91M 5.03M 65.58M 5.12M 5.01M 217M -
Net income -314K -428K -367K -344K -593K -40.82M -598K -4.05M -1.58M -20.59M -1.61M -1.57M -68.19M -
Net Debt -266K -363K -311K -291K -502K -34.58M -507K -3.43M -1.34M -17.44M -1.36M -1.33M -57.77M -
Logo Physiomics Plc
Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.
Employees
-